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INTRODUCTION 
Nasal polyposis (NP), which is a heterogeneous, chronic, in-
flammatory disease of the sinuses, is often associated with asth-
ma
1,2 and is characterized by a mixed Th1 and Th2 immune re-
sponse.
2,3 Although the precise mechanisms underlying the 
pathologic mechanisms of NP are not well-defined, nasal pol-
yps have recently been reported to be characterized by the pres-
ence of numerous eosinophils, activated mast cells, and Th2-
type cells.
2-4 In addition, the numbers of Th2-type cells are in-
creased, irrespective of the patient’s atopic status. Studies have 
also demonstrated strong local upregulation of IL-13, thymus 
and activation-related chemokine (TARC), and immunoglobu-
lin E (IgE) synthesis with the formation of specific IgE to Staph-
ylococcus aureus enterotoxins, suggesting a possible role for su-
perantigens in these pathologic processes.
5,6 Recent studies have 
also suggested that S. aureus secretes exotoxins that act as su-
perantigens and upregulate the variable beta region of lympho-
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cytes in chronic hyperplastic sinusitis with nasal polyposis.
7 
More recently, we have demonstrated increased expression of 
thymic stromal lymphopoietin (TSLP) in nasal polyps, irrespec-
tive of the atopic status of the patient, as compared to the level 
of expression in allergic nasal mucosa.
8 The level of TSLP ex-
pression was in good correlation with the levels of eosinophils 
and IgE in the nasal polyps, suggesting a crucial role for TSLP in 
driving the severity of Th2-type inflammation in the nasal pol-
yps and increased eosinophilia. 
Forkhead box P3 (FOXP3) plays important roles in the devel-
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Purpose:  The pathogenesis of nasal polyposis (NP) is unclear. Eosinophils and mast cells are considered to play important roles in this process. In 
addition, the levels of Th2-type cells are increased, irrespective of the atopic status of the patient with NP. In this context, we and others have shown 
high levels of thymus and activation-related chemokine/CCL17, macrophage-derived chemokine, eotaxin, and RANTES in patients with NP. Forkhead 
box P3 (FOXP3) plays a key role in CD4+CD25+ regulatory T-cell function and represents a specific marker for regulatory T cells (Tregs). Decreased 
expression of FOXP3 has been reported in allergic diseases. The present study was designed to evaluate the presence and potential roles of Tregs, 
defined by the expression of FOXP3 protein, in NP.  Methods:  Using immunohistochemistry, we estimated the numbers of FOXP3+ cells in the epi-
thelium and lamina propria of the NPs of 17 patients with chronic rhinosinusitis with NP and the nasal mucosa of 15 patients with allergic rhinitis 
(AR). The number of FOXP3+ cells in NPs was compared with that in the nasal mucosa of patients with AR, and the numbers of FOXP3+ cells in 
atopic and non-atopic NP were also compared.  Results:  The number of FOXP3+ cells in the lamina propria of patients with NP was significantly 
lower than that in the nasal mucosa of the AR patients (2.79 vs. 5.99, P=0.008). There was no statistically significant difference noted for the num-
bers of FOXP3+ cells between the epithelium of the NP and the nasal mucosa (3.60 vs. 2.39, P=0.180). Furthermore, the numbers of CD4+FOXP3+ 
cells were lower in NPs than in the allergic nasal mucosa. There was no difference in the number of FOXP3+ cells between the atopic and non-atop-
ic NP patients.  Conclusions:  Fewer Tregs (i.e., decreased FOXP3 expression) are found in NPs than in the nasal mucosa of AR patients. As the se-
verity of eosinophilic, Th2-type inflammation and the levels of inflammatory mediators are much higher in NPs than in the nasal mucosa of AR pa-
tients, an inverse co-relationship may exist between these parameters and the number of Tregs. The deficiency of Tregs in NP may account for the 
more pronounced Th2-type inflammation seen in these patients. 
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opment and function of CD4(+) regulatory T cells (Tregs) and 
represents a specific marker for these cells. Tregs are important 
in balancing immune responses and maintaining peripheral 
tolerance. Defects in Tregs have been implicated in the patho-
genesis of chronic inflammatory and autoimmune diseases, 
such as idiopathic thrombocytopenic purpura, burning mouth 
syndrome, and allograft rejection, which have decreased expres-
sion of FOXP3.
9-11 This may reflect the importance of FOXP3 for 
the maintenance of normal tissues. Current evidence suggests 
that allergic disease and asthma are also characterized by defi-
ciencies in Tregs, which allow Th2 cells to expand.
12-14 Despite 
the observed increases inTh2-type cells and IgE levels in the 
nasal polyps, irrespective of the patient’s atopic status, there are 
no studies comparing the numbers of Tregs in nasal polyps and 
allergic nasal mucosa.
To study the role of FOXP3 in the pathogenesis of nasal polyps, 
we compared the levels of FOXP3 expression in the nasal pol-
yps and nasal mucosa of patients with allergic rhinitis. 
MATERILAS AND METHODS
Seventeen patients with NP (12 males and 5 females; mean 
age, 30.6 years) were included in this study. Two of the enrolled 
patients had asthma. Seven of the patients with NP were atopic 
with perennial allergic rhinitis (PAR) and ten of them were non-
atopic. Six of the PAR patients with NP had typical nasal allergy 
to house dust mite (HDM) and one had nasal allergy to cat and 
dog dander, as diagnosed using history and the radioallergo-
sorbent test (RAST). Of the six patients with HDM allergy, four 
also had seasonal allergic rhinitis to Japanese cedar pollen. In 
the present study, we also included fifteen patients with PAR (13 
males and 2 females; mean age, 28.75 years) who had typical 
clinical symptoms of nasal allergy, comprising sneezing, rhi-
norrhea and nasal congestion, and positive serum-specific IgE, 
as analyzed by RAST. 
The diagnosis of allergic rhinitis (AR) was based on a history 
of clinical symptoms of sneezing, rhinorrhea, and nasal con-
gestion, clinical examination by anterior rhinoscopy and, when 
there was a positive history, a positive serum-specific IgE by 
RAST. All patients were symptomatic at the time of collecting 
the specimens and none of them had previously received im-
munotherapy. Nasal polyp specimens and nasal mucosal tissue 
samples were collected at surgery performed as part of the treat-
ment either for the removal of nasal polyps or for the resection 
of hypertrophied turbinates. All medications were prohibited 
for at least one month prior to surgery. The study was approved 
by the Nippon Medical School Medical Ethics Committee and 
informed consent was obtained from all patients. 
Collection and processing of specimens
Nasal polyp tissues were obtained at surgery done as a part of 
the treatment for the removal of nasal polyps (polypectomy/
functional endoscopic sinus surgery). Nasal mucosal speci-
mens were obtained at surgery (conchotomy) performed for 
the treatment of hypertrophied turbinates. Both nasal polyp 
specimens and nasal mucosal tissue specimens (3×4 mm) 
were rinsed in phosphate-buffered saline (PBS; pH 7.6), and 
then processed for immunohistochemistry as described below. 
Immunohistochemistry for the detection of FOXP3 
The nasal polyp and nasal mucosa tissue specimens were first 
fixed in periodate lysine paraformaldehyde (PLP), and then in-
cubated for 4 hours each in gradients of sucrose that varied from 
10% to 20% in PBS. Subsequently, the specimens were embed-
ded in Tissue Tech OCT compound, frozen in liquid nitrogen, 
and stored at −80°C until further use. To investigate the expres-
sion of FOXP3 and to localize the protein in the nasal polyps 
and nasal mucosa, immunohistochemistry was performed.
For immunohistochemistry, frozen sections of PLP-fixed 
specimens were cut at 5-µm thickness using a cryostat (Sakura 
Finetek, Tokyo, Japan), air-dried for 30 minutes, and then fixed 
in acetone for 10 minutes. Immunohistochemistry was per-
formed using the peroxidase-based avidin-biotin complex (ABC) 
method (Vectastain ABC kit; Vector Laboratories, Burlingame, 
CA, USA). Briefly, acetone-fixed sections were rehydrated by 
incubation in Tris-buffered saline (TBS; pH 7.4). Thereafter, the 
specimens were incubated in 10% H2O2 for 30 minutes to block 
endogeneous peroxidase. After two rinses in TBS, the specimens 
were incubated for 45 minutes in Protein Block Serum Free 
Ready to Use (Dako, Glostrup, Denmark). After two rinses in 
TBS, the sections were incubated overnight at 4°C in the opti-
mal concentration of primary mouse monoclonal antibody 
against FOXP3 (5 µg/mL) (clone 236A/E7, sc-56680, lot # K2707; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). IHC staining 
was then performed using the HRP method according to the 
manufacturer’s instructions. After rinsing in TBS that contained 
0.1% Tween-20 (TBS-t; pH 7.6), the sections were incubated in 
the ABC. The sections were then rinsed in TBS-t. Specific im-
munoreactivity of the anti-FOXP3 antibodies was visualized by 
incubating the tissues in multiple-adsorption biotinylated sec-
ondary horse anti-mouse IgG antibody (1:200 dilution, Vecta-
stain Elite ABC Reagent; Vector Laboratories) and the 3-amino-
9-ethyl carbazole (AEC) substrate chromogen (Ready to Use 
kit; Dako). All rinses were carried out in TBS-t (pH 7.6) at room 
temperature. The reaction was stopped by immersing in distilled 
water. The sections were counterstained with Mayer’s hematox-
ylin and mounted in glycergel mounting medium (C0563; Dako). 
As a negative control, the primary antibodies were substituted 
with an irrelevant isotype-matched mouse IgG (IgG1; Dako). 
Double-immunohistochemistry for the detection of 
FOXP3+CD4+ cells 
Although FOXP3 is a biomarker of Tregs, it also expressed in 
some non-CD4+ cells.
16 To confirm that the FOXP3+ cells are Roongrotwattanasiri et al.
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Tregs, we assessed FOXP3 and CD4 expression by double-im-
munohistochemistry using the labeled streptavidin biotin (LSAB) 
and alkaline phosphatase methods, so as to identify FOXP3+ 
CD4+ cells.
15 Processing of the tissue samples for double-im-
munohistochemistry was performed as previously described 
for single staining for FOXP3. For double-immunohistochemis-
try, we performed the first immunostaining with HRP, as in the 
previous single immunohistochemistry, using HRP label detec-
tion with 3,3’-diaminobenzidine (DAB-brown) for the first pri-
mary FOXP3 mouse mAb (clone 236/E7; AbD Serotec, Kidling-
ton, UK). Subsequently, the tissue sections were incubated in 
an elution buffer of 10 mM citrate and 0.05% Tween-20 (pH6.0), 
which had been heated to 60°C for 10 minutes before the sec-
ond immunohistochemistry, which involved the alkaline phos-
phatase-labeled detection system with Fast Red Substrate Sys-
tems (Dako) for the anti-CD4 mouse mAb (clone MT 310, sc-
19641; Santa Cruz Biotechnology). For the negative control, the 
second primary antibodies were substituted with an irrelevant 
isotype-matched mouse IgG (IgG1) (Dako). 
Cell counting 
The numbers of positively stained FOXP3+ cells and FoxP3+ 
CD4+ cells were counted under an Olympus microscope in six 
randomly selected visual fields using an objective micrometer 
in an area of 0.202 mm
2 and at a magnification of 400 HPF. The 
average for the six fields was taken as the cell count for that sec-
tion.
Epithelia and lamina propria were evaluated separately. The 
epithelium, defined as the area between the cilia and basal 
membrane, was evaluated by counting positive cells per 0.0625 
mm
2. The lamina propria, defined as the area immediately un-
derneath the basal membrane, was evaluated by counting pos-
itively stained cells in six randomly selected areas per high-pow-
er field (area: one high-power field at 400× is equivalent to 
0.0625 mm
2). The results are expressed as the number of cells 
per 0.0625 mm
2 in the epithelial and subepithelial areas and 
compared between the nasal mucosa and nasal polyp tissues. 
Statistical analysis
The data are presented as mean±SD. Statistical analyses were 
carried out using the Student’s t-test. Differences were consid-
ered statistically significant only when the P-values were less 
than 0.05. All statistical analyses were performed using the SPSS 
ver. 15 software (SPSS, Chicago, IL, USA).
RESULTS 
Immunohistochemical localization of FOXP3 in nasal polyps 
We analyzed the expression of FOXP3 in nasal polyps. FOXP3 
expression was detected in the inflammatory cells in the epi-
thelium and lamina propria (Fig. 1A). The negative control did 
not show any immunoreactivity for FOXP3 (Fig. 1B). 
Immunohistochemical localization of FOXP3 in the nasal 
mucosa of patients with AR 
We analyzed the expression of FOXP3 in the nasal mucosa of 
patients with allergic rhinitis. FOXP3 expression was detected 
in the inflammatory cells in the epithelium and lamina propria 
(Fig. 2A). The negative control did not show any immunoreac-
tivity for FOXP3 (Fig. 2B). 
Immunolocalization of FOXP3+CD4+ cells in nasal polyps and 
allergic nasal mucosa
A large proportion of the CD4+ cells expressed FOXP3 (Fig. 3A 
and B). Almost all the FOXP3+ cells were CD4+. The negative 
control (isotype-matched IgGs) did not show immunoreactivi-
Fig. 1.  Immunoreactivity and localization of forkhead box P3 (FOXP3) protein in nasal polyps. The immunoreactivity for FOXP3 was analyzed by immunohistochemis-
try using the peroxidase-based avidin-biotin complex method, as described in the text. FOXP3 immunoreactivity is shown in (A), with FOXP3 expression being detected 
mainly in the immune cells of the lamina propria. (B) The negative control shows no immunoreactivity for FOXP3. Magnification ×400 HPF.
A BFOXP3 in Nasal Polyps
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ty for either FOXP3 or CD4 (Fig. 3C).
Comparison of the numbers of FOXP3+ cells in the epithelia 
and lamina propria of nasal polyps
The number of FOXP3+ cells in the epithelia of the nasal pol-
yps group was 2.39±2.33 cells per 0.0625 mm
2. In the lamina 
propria, the number of FOXP3+ cells was 2.79±1.74 per 0.0625 
mm
2 (Fig. 4A). No statistically significant difference was detect-
ed for the number of FOXP3+ cells between the epithelia and 
lamina propria. 
Comparison of the numbers of FOXP3+ cells in the epithelia 
and lamina propria of the nasal mucosa of patients with 
allergic rhinitis
The number of FOXP3+ cells in the epithelia of the nasal mu-
cosa of allergic patients was 3.60±2.64 cells per 0.0625 mm
2. 
The number of FOXP3+ cells in the lamina propria of the nasal 
mucosa of allergic patients (5.99±4.29 cells) was significantly 
higher than that in the epithelial layer (P=0.009) (Fig. 4B). 
Comparison of numbers of FOXP3+ cells in nasal polyps and 
AR nasal mucosa
The numbers of FOXP3+ cells were significantly lower in the 
lamina propria of the nasal polyps than in the lamina propria of 
the nasal mucosa of the AR patients (2.79±1.74 vs. 5.99±4.29, 
P=0.008) (Fig. 5A). Although the number of FOXP3+ cells was 
higher in the epithelia of the allergic nasal mucosa, as compared 
to that in the nasal polyps (3.60±2.64 vs. 2.39± 2.33), the differ-
ence was not statistically significant (Fig. 5B).
Comparison of the number of FOXP3+CD4+ cells in nasal 
polyps from atopics and non-atopics
There was no difference in the numbers of FOXP3+ cells in 
the nasal polyps obtained from atopics and non-atopics, with 
Fig. 2.  Immunoreactivity and localization of forkhead box P3 (FOXP3) in the nasal mucosa of patients with allergic rhinitis. Immunoreactivity for FOXP3 was analyzed 
by immunohistochemistry using the peroxidase-based avidin-biotin complex method, as described in the text. FOXP3 immunoreactivity is shown in (A), with many 
FOXP3-expressing cells being evident in the lamina propria. (B) The negative control shows no immunoreactivity for FOXP3. Magnification ×400 HPF.
A B
Fig. 3.  Immunoreactivity and localization of forkhead box P3 (FOXP3)+CD4+ cells. Double-staining using labeled streptavidin biotin (LSAB) detection with 3,3’-diami-
nobenzidine (DAB-brown) for FOXP3 expression and LSAB alkaline phosphatase detection with Fast Red substrate (red) for CD4+ cells was performed as described 
in the text (A). Symbols used: ☆, FOXP3+/CD4+ cell; △, FOXP3-/CD4+ cell. (B) Double-staining with anti-FOXP3 mAb and IgG1 (negative control for CD4). The arrow 
indicates FOXP3+ cells. Immunoreactivity is evident for only FOXP3+ cells. There is no immunoreactivity for IgG1. (C) The negative control for both FOXP3 and CD4 
shows no immunoreactivity for FOXP3 or CD4. Magnification ×400 HPF
A B CRoongrotwattanasiri et al.
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respect to both the epithelia (2.70±1.90 vs. 2.07±2.71) and 
lamina propria (3.52±2.04 vs. 2.25±1.41). 
Comparison of the numbers of FOXP3+CD4+ cells in nasal 
polyps and allergic nasal mucosa. 
Double immunohistochemistry for FOXP3 and CD4 was per-
formed to detect cells that stained positively for both FOXP3 
and CD4. The number of FOXP3+CD4+ cells was significantly 
higher in the nasal mucosa of the AR patients than in the nasal 
polyps (84.83%±5.73 % vs. 63.18%±15.59%, P=0.002) (Fig. 6).
DISCUSSION 
Tregs represent a subset of CD4+ cells that suppresses the 
functions of other lymphocytes and are characterized by sur-
face expression of CD4 and CD25 and nuclear expression of the 
transcription factor FOXP3. Recently, many functions of FOXP3 
and its influence on the immune system have been elucidated. 
Tregs influence the development and expression of atopy and 
the allergic response.
9-11 Adaptive FOXP3+ Tregs are essential 
for establishing mucosal tolerance and for suppressing IL-4 
production.
17 Decreased expression of FOXP3 has been report-
ed in asthma and allergic rhinitis,
12,18 although there have been 
no studies to compare FOXP3 expression in nasal polyps and 
Fig. 4.  (A) The numbers of forkhead box P3 (FOXP3)-positive cells in the epithe-
lia and lamina propria of nasal polyps. Immunoreactivity for FOXP3 was analyzed 
by immunohistochemistry using the peroxidase-based avidin-biotin complex 
(ABC) method, as described in the text. Positively stained cells were counted as 
described in the text. Magnification ×400 HPF. There is no statistically signifi-
cant difference between the numbers of FOXP3+ cells in the epithelia and lami-
na propria. (B) The numbers of FOXP3+ cells in the epithelia and lamina propria 
of the nasal mucosa of patients with allergic rhinitis. Immunoreactivity for 
FOXP3 was analyzed by immunohistochemistry using the peroxidase-based 
ABC method, as described in the text. Positively stained cells were counted as 
described in the text. Magnification ×400 HPF. The number of FOXP3+ cells is 
significantly higher in the lamina propria than in the epithelium. *P<0.01.
Fig. 5.  (A) Comparison of the numbers of forkhead box P3 (FOXP3)-positive cells 
in the lamina propria of nasal polyps and allergic nasal mucosa. Immunoreac-
tivity for FOXP3 was analyzed by immunohistochemistry using the peroxidase-
based avidin-biotin complex (ABC) method, as described in the text. Positively 
stained cells were counted as described in the text. Magnification ×400 HPF. 
The number of FOXP3+ cells is significantly lower in the lamina propria of the 
nasal polyps than in those of the allergic nasal mucosa. *P<0.01. (B) Compari-
son of the numbers of FOXP3+ cells in the epithelia of nasal polyps and allergic 
nasal mucosa. Immunoreactivity for FOXP3 was analyzed by immunohistochem-
istry using the peroxidase-based ABC method, as described in the text. Posi-
tively stained cells were counted as described in the text. Magnification ×400 
HPF. Although the number of FOXP3+ cells is higher in the epithelia of the aller-
gic nasal mucosa than in those of the nasal polyps, the difference is not statis-
tically significant (NS).
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Fig. 6.  Comparison of the numbers of forkhead box P3 (FOXP3)-positive cells in 
the epithelia of nasal polyps and allergic nasal mucosa. Double-staining for 
FOXP3 and CD4 was performed as described in the text. The number of 
FOXP3+CD4+ cells in the nasal mucosa of allergic rhinitis patients is significant-
ly higher than that in the nasal polyps. *P<0.01.FOXP3 in Nasal Polyps
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allergic nasal mucosa or to define the role of Tregs in NP patho-
genesis. In the present study, we compared the levels of FOXP3 
expression in allergic nasal mucosa and nasal polyps and dem-
onstrated lower expression of FOXP3 in nasal polyps.
Recently, NPs were characterized by a polarized Th2 reaction 
and eosinophilic inflammation and high IgE levels, irrespective 
of atopic status. We have recently reported that high-level ex-
pression of TSLP correlates strongly with the numbers of eosin-
ophils in nasal polyps and also IgE, irrespective of atopic sta-
tus.
8 In the present study, we demonstrate decreased numbers 
of FOXP3+ cells in nasal polyps, as compared to allergic nasal 
mucosa. These lower numbers of FOXP3+ cells observed in pa-
tients with NP may result in unopposed overexpression of Th2 
cells and the increased migration and activation of dendritic 
cells, eosinophils, and mast cells. 
High IgE concentrations have been found in nasal polyps, in-
dicating that IgE is produced locally.
19-21 Suh et al.
20 also report-
ed a polyclonal hyper-immunoglobulinemia E, associated with 
the presence of IgE specific for S. aureus enterotoxins (SAE), 
colonization with S. aureus, and increased eosinophilic inflam-
mation in a relevant subgroup (about 50%) of nasal polyp pa-
tients. These authors also reported a strong correlation between 
the levels of IgE in nasal polyps and the presence of nasal eosin-
ophils. Our recent study demonstrates that the high levels of 
IgE seen in nasal polyps are in good correlation with the num-
ber of TSLP+ cells in nasal polyps as well as between TSLP and 
eosinophils, irrespective of atopic status.
8 Moreover, the levels 
of TARC/CCL17 and macrophage-derived chemokine (MDC) 
were also high in the nasal polyps.
8 In the present study, we also 
found lower numbers of CD4+FOXP3+ cells in the nasal polyps 
than in the allergic nasal mucosa, irrespective of atopic status. 
It has been suggested that S. aureus secretes exotoxins that 
may act as superantigens and upregulate the variable beta re-
gion of lymphocytes in chronic hyperplastic sinusitis with NP.
7 
Recently, Van Bruaene et al.
22 reported lower expression of 
FOXP3 mRNA in chronic rhinosinusitis. In the present study, 
we compared the levels of expression of FOXP3 in the nasal 
mucosa of patients with AR and NP, as well as in the nasal pol-
yps from atopics and non-atopics. While the numbers of Tregs 
in the nasal mucosa of patients with AR are reported to be low, 
we detected a decrease in the number of CD4
+FOXP3
+ Tregs in 
both the atopic and non-atopic nasal polyps. In this context, 
Pérez Novo et al.
23 recently assessed the effect of S. aureus en-
terotoxin B (SEB) on T-cell activation in patients with nasal pol-
yps and asthma, and its possible link to aspirin hypersensitivity. 
SEB significantly increased the levels of IFN-γ, IL-4, TNF-α, IL-
5, and IL-2 in the supernatants of both NP polyp groups with 
asthma but with and without aspirin sensitivity compared with 
controls. The baseline level of FOXP3 was significantly decreased 
in both NP-asthma groups. After incubation with SEB, FOXP3 
was significantly up-regulated in the control group, but not in 
the NP-asthma groups. These researchers concluded that al-
though SEB induces both Th1 and Th2 pro-inflammatory re-
sponses in patients with NP and asthma, regardless of the pres-
ence of aspirin hypersensitivity, the nature of this response may 
be linked to the basal deficiency of FOXP3 observed in the NP-
asthma patients. Therefore, the deficiency of FOXP3 may lead 
to the enhanced Th2 inflammation in the NP of atopics and 
non-atopics and the high level of IgE, irrespective of the atopic 
status.
These data suggest that the suppressive function of Tregs may 
be partially inhibited. This might partially explain the more pro-
nounced Th2-type inflammation and eosinophilic inflamma-
tion in nasal polyps, as compared to the allergic nasal mucosa. 
Furthermore, there is no reported statistically significant differ-
ence between the lymphocyte subpopulations of atopic and 
non-atopic patients.
24,25 
Taken together, the present findings indicate that the deficien-
cy of Tregs in nasal polyps may play an important role in en-
hancement of the severity of Th2 inflammation in nasal polyps 
and the persistence and progression of NP. Furthermore, these 
results point to increasingly important roles for T cells in chron-
ic rhinosinusitis with nasal polyposis.
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